NCT05447117

Subthreshold Micropulse Laser Treatment of Acute Central Serous Chorioretinopathy

Subthreshold Micropulse 532 nm Green Laser Treatment of Acute Central Serous Chorioretinopathy: 18-month Results

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Minia University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of 532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).

Detailed description

This prospective study included 42 eyes of 42 patients with acute CSCR treated with IRIDEX™ IQ 532 nm GSML. The study was conducted at Minia University Hospital and Genaidy Ophthalmology Center, Minia, Egypt between October 2019 and May 2022. All patients were subjected to a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT) at baseline and each follow-up visit 1, 3 and 18 months after laser treatment

Conditions

• Acute Central Serous Retinopathy With Subretinal Fluid

Interventions

Type	Name	Description
PROCEDURE	Micropulse laser	532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).

Timeline

• Start date: 2019-10-15
• Primary completion: 2022-05-30
• Completion: 2022-06-30
• First posted: 2022-07-07
• Last updated: 2022-09-13

Locations

1 site across 1 country: Egypt